Mohammed Tredano, Jacques de Blic, Matthias Griese, Jean-Christophe Fournet, Jacques Elion, Michel Bahuau
Clinical Biological and Genetic Heterogeneity of the Inborn Errors of Pulmonary Surfactant Metabolism
Pulmonary surfactant is a multimolecular complex located
at the air-water interface within the alveolus to
which a range of physical (surface-active properties)
and immune functions has been assigned. This complex
consists of a surface-active lipid layer (consisting mainly
of phospholipids), and of an aqueous subphase. From
discrete surfactant sub-fractions one can isolate
strongly hydrophobic surfactant proteins B (SP-B) and C
(SP-C) as well as collectins SP-A and SP-D, which were
shown to have specific structural, metabolic, or immune
properties. Inborn or acquired abnormalities of the
s u rfactant, qualitative or quantitative in nature, account
for a number of human diseases. Beside hyaline membrane
disease of the preterm neonate, a cluster of hereditary
or acquired lung diseases has been characterized
by periodic acid-Schiff-positive material filling the alveoli.
From this heterogeneous nosologic group, at least
two discrete entities presently emerge. The first is the
SP-B deficiency, in which an essentially proteinaceous
material is stored within the alveoli, and which represents
an autosomal recessive Mendelian entity linked to
the SFTPB gene (MIM 1786640). The disease usually
generally entails neonatal respiratory distress with
rapid fatal outcome, although partial or transient deficiencies
have also been observed. The second is alveolar
proteinosis, characterized by the storage of a mixed
protein and lipid material, which constitutes a relatively
heterogeneous clinical and biological syndrome, especially
with regard to age at onset (from the neonate
through to adulthood) as well as the severity of associated
signs. Murine models, with a targeted mutation of
the gene encoding granulocyte macrophage colony-stimulating
factor (GM-CSF) (Csfgm) or the ? subunit of
its receptor (Il3rb1) support the hypothesis of an abnormality
of surfactant turnover in which the alveolar
macrophage is a key player. Apart from SP-B deficiency,
in which a near-consensus diagnostic chart can be designed,
the ascertainment of other abnormalities of surfactant
metabolism is not straightforward. The disentdisentanglement
of this disease cluster is however essential
to propose specific therapeutic procedures: repeated
broncho-alveolar lavages, GM-CSF replacement, bone
marrow grafting or lung transplantation.
Clinical Chemical Laboratory Medicine, Walter de Gruyter
Print ISSN: 1434-6621
Volume: 39, 04/2001
Pages: 90 - 108
Show full article (external site)
Show all available items of this journal